-
Something wrong with this record ?
A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective
J. Jendle, P. Adolfsson, P. Choudhary, K. Dovc, A. Fleming, DC. Klonoff, JK. Mader, N. Oliver, JL. Sherr, J. Šoupal, L. Heinemann
Language English Country Germany
Document type Journal Article, Review
Grant support
UL1 TR001863
NCATS NIH HHS - United States
NLK
ProQuest Central
from 1999-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1999-01-01 to 1 year ago
Public Health Database (ProQuest)
from 1999-01-01 to 1 year ago
- MeSH
- Diabetes Mellitus * drug therapy MeSH
- Electronic Health Records MeSH
- Blood Glucose MeSH
- Humans MeSH
- Blood Glucose Self-Monitoring * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Geographicals
- United Kingdom MeSH
People living with diabetes have many medical devices available to assist with disease management. A critical aspect that must be considered is how systems for continuous glucose monitoring and insulin pumps communicate with each other and how the data generated by these devices can be downloaded, integrated, presented and used. Not only is interoperability associated with practical challenges, but also devices must adhere to all aspects of regulatory and legal frameworks. Key issues around interoperability in terms of data ownership, privacy and the limitations of interoperability include where the responsibility/liability for device and data interoperability lies and the need for standard data-sharing protocols to allow the seamless integration of data from different sources. There is a need for standardised protocols for the open and transparent handling of data and secure integration of data into electronic health records. Here, we discuss the current status of interoperability in medical devices and data used in diabetes therapy, as well as regulatory and legal issues surrounding both device and data interoperability, focusing on Europe (including the UK) and the USA. We also discuss a potential future landscape in which a clear and transparent framework for interoperability and data handling also fulfils the needs of people living with diabetes and healthcare professionals.
3rd Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Paediatrics The Hospital of Halland Kungsbacka Kungsbacka Sweden
Diabetes Research Centre University of Leicester Leicester UK
Diabetes Research Institute Mills Peninsula Medical Center San Mateo CA USA
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Institute of Clinical Sciences Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden
School of Medicine Institute of Medical Sciences Örebro University Örebro Sweden
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007378
- 003
- CZ-PrNML
- 005
- 20240423155917.0
- 007
- ta
- 008
- 240412s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00125-023-06049-5 $2 doi
- 035 __
- $a (PubMed)38041737
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Jendle, Johan $u School of Medicine, Institute of Medical Sciences, Örebro University, Örebro, Sweden. johan.jendle@oru.se $1 https://orcid.org/0000000310251682
- 245 12
- $a A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective / $c J. Jendle, P. Adolfsson, P. Choudhary, K. Dovc, A. Fleming, DC. Klonoff, JK. Mader, N. Oliver, JL. Sherr, J. Šoupal, L. Heinemann
- 520 9_
- $a People living with diabetes have many medical devices available to assist with disease management. A critical aspect that must be considered is how systems for continuous glucose monitoring and insulin pumps communicate with each other and how the data generated by these devices can be downloaded, integrated, presented and used. Not only is interoperability associated with practical challenges, but also devices must adhere to all aspects of regulatory and legal frameworks. Key issues around interoperability in terms of data ownership, privacy and the limitations of interoperability include where the responsibility/liability for device and data interoperability lies and the need for standard data-sharing protocols to allow the seamless integration of data from different sources. There is a need for standardised protocols for the open and transparent handling of data and secure integration of data into electronic health records. Here, we discuss the current status of interoperability in medical devices and data used in diabetes therapy, as well as regulatory and legal issues surrounding both device and data interoperability, focusing on Europe (including the UK) and the USA. We also discuss a potential future landscape in which a clear and transparent framework for interoperability and data handling also fulfils the needs of people living with diabetes and healthcare professionals.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a selfmonitoring glykemie $7 D015190
- 650 _2
- $a krevní glukóza $7 D001786
- 650 12
- $a diabetes mellitus $x farmakoterapie $7 D003920
- 650 _2
- $a elektronické zdravotní záznamy $7 D057286
- 651 _2
- $a Spojené království $7 D006113
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Adolfsson, Peter $u Department of Paediatrics, The Hospital of Halland Kungsbacka, Kungsbacka, Sweden $u Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden $1 https://orcid.org/0000000176159737
- 700 1_
- $a Choudhary, Pratik $u Diabetes Research Centre, University of Leicester, Leicester, UK $1 https://orcid.org/0000000176354735
- 700 1_
- $a Dovc, Klemen $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $u Department of Paediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Ljubljana, Slovenia $1 https://orcid.org/0000000192012145
- 700 1_
- $a Fleming, Alexander $u Kinexum, Harpers Ferry, WV, USA $1 https://orcid.org/0000000265490288
- 700 1_
- $a Klonoff, David C $u Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA $1 https://orcid.org/0000000163946862
- 700 1_
- $a Mader, Julia K $u Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria $1 https://orcid.org/0000000178544233
- 700 1_
- $a Oliver, Nick $u Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK $1 https://orcid.org/0000000335253633
- 700 1_
- $a Sherr, Jennifer L $u Yale University School of Medicine, New Haven, CT, USA $1 https://orcid.org/0000000193013043
- 700 1_
- $a Šoupal, Jan $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/000000016041190X $7 xx0224300
- 700 1_
- $a Heinemann, Lutz $u Science Consulting in Diabetes GmbH, Düsseldorf, Germany $1 https://orcid.org/0000000324931304
- 773 0_
- $w MED00001391 $t Diabetologia (Berlin) $x 1432-0428 $g Roč. 67, č. 2 (2024), s. 236-245
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38041737 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155913 $b ABA008
- 999 __
- $a ok $b bmc $g 2081385 $s 1217145
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 67 $c 2 $d 236-245 $e 20231202 $i 1432-0428 $m Diabetologia (Berlin) $n Diabetologia $x MED00001391
- GRA __
- $a UL1 TR001863 $p NCATS NIH HHS $2 United States
- LZP __
- $a Pubmed-20240412
